Has Selecta found a way around gene therapy's delivery problem? Takeda puts down $1B-plus to find out
While gene therapies were traditionally thought of as one-and-done treatments, scientists now see a benefit in redosing patients down the road. The only problem? Some patients mount an immune response to the adeno-associated viruses (AAV) used to deliver the therapies.
It’s one of gene therapy’s most pressing issues, and a raft of companies are working on non-viral delivery methods to get around it. But Selecta Biosciences thinks it’s found another way to tamp down the body’s immune response — and Takeda is ready to dole out more than $1 billion to get in on the action.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
